Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for detection of significant prostate cancer, part 2: cost-effectiveness analysis. J Nucl Med. 2019 Dec;60(12):1705-12. doi: 10.2967/jnumed.119.225771
Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.
Chambers TM, Agopian AJ, Lewis RA, Langlois PH, Danysh HE, Weber KA, Shaw GM, Mitchell LE, Lupo PJ. Epidemiology of anophthalmia and microphthalmia: prevalence and patterns in Texas, 1999-2009. Am J Med Genet A. 2018 Sep;176(9):1810-8. doi: 10.1002/ajmg.a.40352
Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017 Jul;13(4):207-20. doi: 10.5055/jom.2017.0389
Ronquest N, Wollschlaeger B, Montejano L, Wilson T, Nadipelli V. Characteristics and treatment patterns of US medicaid patients with opioid use disorder. Poster presented at the 2016 International Conference on Opioids Conference; June 2016. Boston, MA. [abstract] J Opioid Manag. 2016 May; 12(3):227.
Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey DBJr. Anxiety, attention problems, hyperactivity, and the aberrant behavior checklist in fragile x syndrome. Am J Med Genet A. 2014 Jan;164A(1):141-55. doi: 10.1002/ajmg.a.36232
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.